SCHEMBL895897

SCHEMBL895897

NOC(=O)CC(=O)ON

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3204762 0.90
SCHEMBL895898 0.83
SCHEMBL563089 0.81
SCHEMBL4939831 0.81 GAA (0.75)
SCHEMBL28657001 0.81 ALDH1A1 (0.43)
SCHEMBL1924739 0.79 DGAT1 (0.38)
SCHEMBL14996454 0.78 OR51E2 (0.36)
SCHEMBL468549 0.77 TSHR (0.44)
SCHEMBL10538334 0.76
SCHEMBL15800537 0.76 LDHA (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619046-A1 ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE Genome & Company, Inc. (KR) 2025-09-24 EP claimed
WO-2024107014-A1 ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE GENOME AND COMPANY (KR) 2024-05-23 WO claimed
US-20160011168-A1 METHOD FOR JUDGING PRESENCE OR ABSENCE OF EPITHELIAL-MESENCHYMAL TRANSITION SHIMADZU CORPORATION (JP) 2016-01-14 US claimed
CN-101590241-B Cisplatin nano-micelle prodrug and preparation method thereof SH NAT ENG RES CT NANOTECH CO 2011-03-30 CN claimed
CN-101590241-A Cisplatin nano-micelle prodrug and preparation method thereof SH NAT ENG RES CT NANOTECH CO (CN) 2009-12-02 CN claimed
EP-0989113-B1 A PROCESS FOR PREPARING 2-AMINOMALONIC ACID DERIVATIVES TAITO CO (JP) 2004-11-10 EP claimed
US-20010008945-A1 PROCESS FOR PREPARING 2-AMINO MALONIC ACID DERIVATIVES AND 2-AMINO-1,3 - PROPANEDIOL DERIVATIVES, AND INTERMEDIATES FOR PREPARING THE SAME MITSUBISHI PHARMA CORPORATION (JP) 2001-07-19 US claimed
US-6221906-B1 ANTICANCER AGENTS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2001-04-24 US claimed
EP-1082331-A1 PLATINUM COMPLEX CONJUGATED TO CYCLOTRIPHOSPHAZENE, ITS PREPARATION, AND ANTICANCER AGENT COMPRISING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2001-03-14 EP claimed
WO-2000058321-A1 PLATINUM COMPLEX CONJUGATED TO CYCLOTRIPHOSPHAZENE, ITS PREPARATION, AND ANTICANCER AGENT COMPRISING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2000-10-05 WO claimed
EP-0989113-A1 PROCESSES FOR PRODUCING 2-AMINOMALONIC ACID DERIVATIVES AND 2-AMINO-1,3-PROPANEDIOL DERIVATIVES, AND INTERMEDIATES FOR PRODUCING THE DERIVATIVES TAITO CO., LTD. (JP) 2000-03-29 EP claimed
EP-0832110-A1 ANTIVIRAL PEPTOID COMPOUNDS Novartis AG (CH) 1998-04-01 EP claimed
WO-1996040759-A1 ANTIVIRAL PEPTOID COMPOUNDS NOVARTIS AG (CH) 1996-12-19 WO claimed
US-4793986-A POLYSACCHARIDE CARRIER, ACTIVATED, LINKED TO PLATINUM COMPOUND THROUGH AMINE-CONTAINING LIGAND JOHNSON MATTHEY, INC. (US) 1988-12-27 US claimed
EP-4619046-A1 ANTI-BASAL CELL ADHESION MOLECULE ANTIBODY-DRUG CONJUGATE Genome & Company, Inc. (KR) 2025-09-24 EP disclosed
US-20250249113-A1 LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) 2025-08-07 US disclosed
EP-4507734-A1 LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES Debiopharm Research & Manufacturing S.A. (CH) 2025-02-19 EP disclosed
WO-1991018523-A1 INGESTIBLES CONTAINING SUBSTANTIALLY TASTELESS SWEETNESS INHIBITORS AS BITTER TASTE REDUCERS OR SUBSTANTIALLY TASTELESS BITTER INHIBITORS AS SWEET TASTE REDUCERS BIORESEARCH, INC. (US) 1991-12-12 WO disclosed
EP-0279832-A1 ENZYMATIC PROCESS CELLTECH LIMITED (GB) 1988-08-31 EP disclosed
WO-1988001650-A1 ENZYMATIC PROCESS CELLTECH LIMITED (GB) 1988-03-10 WO disclosed